Henry F Chambers

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/151754/henry-f-chambers-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87 papers	9,221 citations	30 h-index	95 g-index
95 ext. papers	10,982 ext. citations	10.8 avg, IF	6.25 L-index

#	Paper	IF	Citations
87	Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.. *JAMA Pediatrics*, **2022**,	8.3	7
86	Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Bloodstream Infections.. *Open Forum Infectious Diseases*, **2022**, 9, ofab651	1	1
85	Impacts of NaHCO on -Lactam Binding to PBP2a Protein Variants Associated with the NaHCO-Responsive versus NaHCO-Non-Responsive Phenotypes.. *Antibiotics*, **2022**, 11,	4.9	1
84	Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX.. *MBio*, **2022**, e0049722	7.8	2
83	The NaHCO-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by Genotype.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0025222	5.9	0
82	Loss of GdpP function in leads to -lactam tolerance and enhanced evolution of -lactam resistance. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0143121	5.9	0
81	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. *Lancet Infectious Diseases, The*, **2021**,	25.5	9
80	Impact of Bicarbonate--Lactam Exposures on Methicillin-Resistant (MRSA) Gene Expression in Bicarbonate--Lactam-Responsive vs. Non-Responsive Strains. *Genes*, **2021**, 12,	4.2	2
79	Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant (MRSA). *Antimicrobial Agents and Chemotherapy*, **2021**,	5.9	5
78	Differential Trends in Extended-Spectrum Beta-Lactamase-Producing Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis. *Microbial Drug Resistance*, **2021**, 27, 154-161	2.9	1
77	Skin and Soft Tissue Infections in Persons Who Inject Drugs. *Infectious Disease Clinics of North America*, **2021**, 35, 169-181	6.5	4
76	Antibacterial Resistance Leadership Group 2.0: Back to Business. *Clinical Infectious Diseases*, **2021**, 73, 730-739	11.6	2
75	Prosthetic Valve Endocarditis Diagnosis and Management- New Paradigm Shift Narratives. *Clinical Infectious Diseases*, **2021**, 72, 1687-1692	11.6	2
74	Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. *Antimicrobial Resistance and Infection Control*, **2021**, 10, 118	6.2	3
73	A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: -Lactam Sensitization among Methicillin-Resistant (MRSA). *Antibiotics*, **2021**, 10,	4.9	3
72	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. *Lancet Infectious Diseases, The*, **2021**, 21, e296-e301	25.5	29
71	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2622-2632	5.1	12

70	Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. *JAMA Internal Medicine*, **2020**, 180, 769-777	11.5	16
69	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. *Lancet Infectious Diseases, The*, **2020**, 20, 731-741	25.5	59
68	Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant. *Journal of Biological Chemistry*, **2020**, 295, 10870-10884	5.4	4
67	Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal Swabs. *Journal of Molecular Diagnostics*, **2020**, 22, 811-816	5.1	4
66	Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO) Responsiveness and Lactam Sensitization in Methicillin-Resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
65	39. Comparative One-year Outcomes of Invasive staphylococcus Aureus infections Among Persons with and Without Drug Use in an Urban West Coast Cohort. *Open Forum Infectious Diseases*, **2020**, 7, S20-S21	1	
64	175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). *Open Forum Infectious Diseases*, **2020**, 7, S216-S216	1	1
63	Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. *JAMA Internal Medicine*, **2020**, 180, 138-139	11.5	1
62	Native-Valve Infective Endocarditis. *New England Journal of Medicine*, **2020**, 383, 567-576	59.2	34
61	The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). *Clinical Infectious Diseases*, **2020**, 70, 1536-1545	11.6	54
60	Bicarbonate Resensitization of Methicillin-Resistant to Lactam Antibiotics. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	17
59	A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection. *Clinical Infectious Diseases*, **2019**, 68, 1502-1511	11.6	30
58	Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	5
57	2276. Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study. *Open Forum Infectious Diseases*, **2019**, 6, S779-S779	1	1
56	607. Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate [NaHCO3]-Responsivity and Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA). *Open Forum Infectious Diseases*, **2019**, 6, S284-S284	1	78
55	Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults. *Clinical Infectious Diseases*, **2019**, 68, 865-872	11.6	25
54	Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of Staphylococcus aureus Bacteremia. *Clinical Infectious Diseases*, **2019**, 69, 530-533	11.6	21
53	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. *Clinical Infectious Diseases* , **2019**, 68, 1823-1830	11.6	27

52	PBP4 activity and its overexpression are necessary for PBP4-mediated high-level β-lactam resistance. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1177-1180	5.1	9
51	PBP4: A New Perspective on β-Lactam Resistance. *Microorganisms*, **2018**, 6,	4.9	16
50	Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in. *Journal of Biological Chemistry*, **2018**, 293, 19854-19865	5.4	25
49	Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	17
48	Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	143
47	High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	27
46	Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
45	PBP4 Mediates β-Lactam Resistance by Altered Function. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	18
44	Antimicrobial Stewardship Approaches in the Intensive Care Unit. *Infectious Disease Clinics of North America*, **2017**, 31, 513-534	6.5	12
43	A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *New England Journal of Medicine*, **2017**, 376, 2545-2555	59.2	112
42	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. *Journal of Clinical Microbiology*, **2017**, 55, 134-144	9.7	22
41	Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. *Open Forum Infectious Diseases*, **2017**, 4, ofx232	1	33
40	IVIG-mediated protection against necrotizing pneumonia caused by MRSA. *Science Translational Medicine*, **2016**, 8, 357ra124	17.5	51
39	Reply to Lesho and Clifford. *Clinical Infectious Diseases*, **2016**, 63, 571-2	11.6	1
38	Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5276-84	5.9	17
37	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. *Clinical Infectious Diseases*, **2016**, 62, 181-9	11.6	44
36	Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. *PLoS ONE* , **2016**, 11, e0149541	3.7	36
35	Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. *Infection and Chemotherapy*, **2016**, 48, 267-273	3.9	74

34	PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3934-41	5.9	25
33	Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3976-9	5.9	10
32	Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2960-3	5.9	57
31	Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3252-6	5.9	14
30	Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. *New England Journal of Medicine*, **2015**, 372, 1093-103	59.2	136
29	Epidemiology of community-associated methicillin-resistant Staphylococcus aureus in San Francisco children. *Journal of Pediatric Infectious Diseases*, **2015**, 04, 247-259	0.4	
28	USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus. *MBio*, **2015**, 6,	7.8	59
27	Antibacterial resistance leadership group: open for business. *Clinical Infectious Diseases*, **2014**, 58, 1571-6	11.6	17
26	Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2014**, 59, e10-52	11.6	856
25	Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clinical Infectious Diseases*, **2014**, 59, 147-59	11.6	1194
24	724Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with Staphylococcus aureus Bacteremia in a Safety-Net Hospital. *Open Forum Infectious Diseases*, **2014**, 1, S204-S204	1	78
23	608Can Rapid Molecular Diagnostics Assist in the Choice of b-Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG). *Open Forum Infectious Diseases*, **2014**, 1, S28-S28	1	1
22	Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. *Clinical Infectious Diseases*, **2014**, 59, 798-807	11.6	66
21	Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 7617	5.9	1
20	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. *Clinical Infectious Diseases*, **2011**, 52, e18-55	11.6	1736
19	Reply to Cataldo et al. *Clinical Infectious Diseases*, **2011**, 53, 310-310	11.6	
18	A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4900-2	5.9	72
17	Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. *Journal of Clinical Investigation*, **2009**, 119, 2464-74	15.9	331

16	Waves of resistance: Staphylococcus aureus in the antibiotic era. *Nature Reviews Microbiology*, **2009**, 7, 629-41	22.2	1590
15	Merle A. Sande: 19392007. *Clinical Infectious Diseases*, **2008**, 46, 1743-1744	11.6	
14	Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. *New England Journal of Medicine*, **2006**, 355, 653-65	59.2	1114
13	Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 884-8	5.9	92
12	Imipenem for treatment of tuberculosis in mice and humans. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 2816-21	5.9	90
11	Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. *Clinical Infectious Diseases*, **2004**, 38, 994-1000	11.6	276
10	Solving staphylococcal resistance to beta-lactams. *Trends in Microbiology*, **2003**, 11, 145-8	12.4	33
9	Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2742-6	5.9	30
8	Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. *Clinical Pharmacology and Therapeutics*, **1996**, 59, 14-21	6.1	51
7	Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. *Journal of Infectious Diseases*, **1995**, 171, 897-902	7	26
6	Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. *Journal of Antimicrobial Chemotherapy*, **1993**, 32, 453-8	5.1	5
5	Treatment of Infection and Colonization Caused by Methicillin-Resistant Staphylococcus aureus. *Infection Control and Hospital Epidemiology*, **1991**, 12, 29-35	2	28
4	Endogenous or Exogenous Origin of Platelet-Activating Factor in Cerebrospinal Fluid of Children with Bacterial Meningitis-Reply. *Journal of Infectious Diseases*, **1991**, 163, 1166-1166	7	
3	Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. *Journal of Infectious Diseases*, **1984**, 149, 894-903	7	52
2	Clinical Manifestations of Community-Acquired MRSA Infections521-537		1
1	Community-Onset Oxacillin-Resistant Staphylococcus aureus Infection85-93		